EGFR and neoplasm: We have recently generated a tumor-targeted 4-1BB-agonistic trimerbody, consisting of three anti-4-1BB single-chain fragment variable (scFv) antibodies, and three anti-EGFR single-domain (VHH) antibodies positioned in an hexagonal conformation around a murine collagen XVIII-derived homotrimerization (TIEXVIII) domain (10).